Greenwich LifeSciences Gains EMA Clearance to Use Commercial GP2 Lots Across FLAMINGO-01 Sites

Greenwich LifeSciences has secured EMA approval to deploy the same commercially manufactured GP2 lot already cleared by the FDA for use across all European FLAMINGO-01 sites, completing a parallel multi-regional regulatory alignment that now covers roughly 170–180 clinical sites in the US and Europe simultaneously.

The manufacturing sequence behind this approval spans several years. Three commercial lots of GP2 active ingredient were produced in 2023 at an approved commercial facility, with capacity estimated at approximately 200,000 doses. Vial-filling at a commercial facility followed in 2024, alongside the initiation of drug stability programs for all four lots. The FDA reviewed submitted lot data and cleared the first commercial vial lot for FLAMINGO-01 use in the US in early 2026; the EMA has now completed its own independent review and reached the same conclusion.

For QA directors and regulatory leads managing clinical-to-commercial transitions, the operational read is direct: all 40–50 US sites are already treating patients with commercial GP2 vials following a distribution model that relies on warehouse partners and a clinical team internalized in Q4 2025. European pharmacy shipments are under way using the identical lot. The company is now pursuing separate regulatory submissions in the UK and Canada, each proceeding through independent national processes.

The trial itself is enrolling at approximately 800 patients per year, with more than 1,300 screened to date. The 250-patient non-HLA-A*02 arm is fully enrolled; a preliminary recurrence-rate analysis following the Primary Immunization Series shows an approximately 70–80% reduction, trending in line with Phase IIb results. Stability data supporting the commercial lots remains active across all four manufactured batches, a dataset that will underpin any further regional submissions.

Regulatory clearance in the UK and Canada will determine whether the single-lot strategy can extend to a fully unified global supply chain for the remainder of the FLAMINGO-01 enrollment period.

Source: Greenwich LifeSciences, Inc. via GlobeNewswire, July 9, 2026.